EHS
EHS

Foundation Medicine Introduces FoundationOne®Liquid, the Latest Advance in the Company’s Liquid Biopsy Test for Solid Tumors in Patients with Advanced Cancer


CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. today announced that FoundationOne®Liquid, its next-generation liquid biopsy test for solid tumors, is commercially available in the United States. Using a blood sample, FoundationOne Liquid analyzes 70 genes known to drive cancer growth, including homologous recombination deficiency (HRD) genes, and reports the genomic biomarker for microsatellite instability (MSI),1 to help inform the use of checkpoint inhibitor immunotherapies and

Source link

EHS
Back to top button